Patent intelligence · US
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
Kappa opioid receptor antagonists and products and methods related thereto
Patent details — US 11897873
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 13, 2024
- Expiration
- Feb 8, 2044
- Applicant
- BLACKTHORN THERAPEUTICS, INC.
- Claims
- 6
- CPC classes
- A61P, A61P25/00, A61P25/06
Quick answer
US 11897873 (Kappa opioid receptor antagonists and products and methods related thereto) is held by BLACKTHORN THERAPEUTICS, INC.. Status: granted. Granted Feb 13, 2024. Expires Feb 8, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BLACKTHORN THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61P, A61P25/00, A61P25/06
More from BLACKTHORN THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 11897873?
US 11897873 (Kappa opioid receptor antagonists and products and methods related thereto) is held by BLACKTHORN THERAPEUTICS, INC.. Status: granted. Granted Feb 13, 2024. Expires Feb 8, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11897873?
BLACKTHORN THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 11897873 expire?
Our index shows an expiration date of Feb 8, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.